"We are pleased that Mr. Elliston has agreed to join our team as President and CEO," says Eli Wilner, Chairman of Advanced Viral Research. "Having held senior management positions in the bio-pharmaceutical field for more than 25 years and covering virtually every facet of the bio-pharmaceutical industry, Mr. Elliston's experience is both critical and relevant to the needs of ADVR at this time," added Wilner.
"I am excited about the challenge to make ADVR a recognized name within the bio- pharmaceutical marketplace. Today, more than ever, bio-tech companies such as ADVR serve an important role in the discovery of new drugs designed to satisfy unmet medical needs. Our team at ADVR will be dedicated towards meeting this challenge," stated Mr. Elliston.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's lead product, AVR118 (formerly known as Product R),represents a complex mixture of peptides, amino acids, nucleosides, nucleotides and nucleic acid bases that possesses, among other things, immunomodulatory activity. We believe it may be employed in the treatment of diseases and conditions such as: Various conditions associated with cancer; cachexia, or body wasting, in patients with acquired immune deficiency syndrome (AIDS), cancer, human immunodeficiency virus, or HIV, including AIDS as a combination therapy; type 2 diabetes; human papilloma virus, or HPV; and rheumatoid arthritis. ADVR is in clinical trials for treatment of cachexia (body wasting) in patients with AIDS.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described From time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable Agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future Events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
Contact: Equity Relations, Inc. Richard Brown, 617-314-7379 staff@equityrelations.com
Source: Advanced Viral Research Corp.
